**RESULTS**

**In vitro**

Table 1: Gene expression profile of SKUT1 cells treated with ARQ 092. The expression levels of various genes were determined by qPCR analysis. ARQ 092 treatment significantly inhibited the expression of AKT2, PIK3CA, and PIK3CB genes compared to control.

**In vivo**

Figure 2: Tumor growth inhibition in ARQ 092-treated mice. The tumor volume was measured at days 1, 3, 5, 7, 9, and 11 post-treatment, and the percentage change in tumor volume was calculated.

**Clinical Phase I Study**

Table 2: Clinical phase I study outcome. The results indicate that ARQ 092 is well-tolerated and shows promising antitumor activity.

**CONCLUSIONS**

ARQ 092 was evaluated in clinical Phase I studies and demonstrated promising antitumor activity and manageable safety profile.

**REFERENCES**